Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125540541 | 12554054 | 1 | I | 20160704 | 20160713 | 20160713 | EXP | US-TEVA-675139USA | TEVA | FREEMAN GM, MARTIN BA, HU RJ. G-CSF DOSING TO PREVENT RECURRENT CLOZAPINE-INDUCED AGRANULOCYTOSIS. AM-J-PSYCHIATRY 2016;173(6):643. | 19.00 | YR | M | Y | 0.00000 | 20160713 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125540541 | 12554054 | 1 | PS | CLOZAPINE. | CLOZAPINE | 1 | Unknown | 700 MG | Y | Y | 74949 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125540541 | 12554054 | 1 | Schizoaffective disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125540541 | 12554054 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125540541 | 12554054 | Agranulocytosis | Agranulocytosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |